Literature DB >> 18619815

Longitudinal progression of negative symptoms in schizophrenia: a new look at an old problem.

Mary E Kelley1, Gretchen L Haas, Daniel P van Kammen.   

Abstract

OBJECTIVE: Longitudinal analysis is crucial in determining the ability of new interventions to successfully reduce negative symptoms in schizophrenia. However, there are still conflicting reports as to whether there are significant treatment effects on these symptoms and the extent of these effects. We examine the possible effects of analysis method on these questions.
METHODS: We use generalized linear mixed models (GLMM) to assess the change in specific negative symptom items following treatment changes in two separate cohorts of schizophrenia patients, one chronic and one first episode.
RESULTS: Both data sets indicate that examining the change in prevalence of moderate to severe symptoms provides a useful estimate of the effect size associated with changes in treatment that often differs from that given using analysis of means.
CONCLUSIONS: The use of categorical longitudinal methods may be critical to determining the responsiveness of negative symptoms to treatment as well as determining the stability of these symptoms over time.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18619815      PMCID: PMC2600772          DOI: 10.1016/j.schres.2008.06.003

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  48 in total

1.  Methods for estimating the parameters of a linear model for ordered categorical data.

Authors:  S R Lipsitz
Journal:  Biometrics       Date:  1992-03       Impact factor: 2.571

2.  A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change.

Authors:  S Arndt; N C Andreasen; M Flaum; D Miller; P Nopoulos
Journal:  Arch Gen Psychiatry       Date:  1995-05

3.  Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication.

Authors:  R Tandon; S C Ribeiro; J R DeQuardo; R S Goldman; J Goodson; J F Greden
Journal:  Biol Psychiatry       Date:  1993-10-01       Impact factor: 13.382

4.  Deficit and nondeficit forms of schizophrenia: the concept.

Authors:  W T Carpenter; D W Heinrichs; A M Wagman
Journal:  Am J Psychiatry       Date:  1988-05       Impact factor: 18.112

5.  Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset.

Authors:  R D Gibbons; D Hedeker; I Elkin; C Waternaux; H C Kraemer; J B Greenhouse; M T Shea; S D Imber; S M Sotsky; J T Watkins
Journal:  Arch Gen Psychiatry       Date:  1993-09

6.  Assessment of enduring deficit and negative symptom subtypes in schizophrenia.

Authors:  K T Mueser; M S Douglas; A S Bellack; R L Morrison
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

7.  Subtype progression and pathophysiologic deterioration in early schizophrenia.

Authors:  T H McGlashan; W S Fenton
Journal:  Schizophr Bull       Date:  1993       Impact factor: 9.306

8.  Effect of antipsychotic withdrawal on negative symptoms in schizophrenia.

Authors:  D D Miller; M Flaum; S Arndt; F Fleming; N C Andreasen
Journal:  Neuropsychopharmacology       Date:  1994-08       Impact factor: 7.853

9.  Structure and course of positive and negative symptoms in schizophrenia.

Authors:  W W Eaton; R Thara; B Federman; B Melton; K Y Liang
Journal:  Arch Gen Psychiatry       Date:  1995-02

10.  Validity of the negative/positive dichotomy for schizophrenic disorders under long-term conditions.

Authors:  A Marneros; A Deister; A Rohde
Journal:  Schizophr Res       Date:  1992-07       Impact factor: 4.939

View more
  4 in total

1.  Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?

Authors:  Philip D Harvey; Alan S Bellack
Journal:  Schizophr Bull       Date:  2009-01-06       Impact factor: 9.306

2.  Measuring pathology using the PANSS across diagnoses: Inconsistency of the positive symptom domain across schizophrenia, schizoaffective, and bipolar disorder.

Authors:  Ariana E Anderson; Maxwell Mansolf; Steven P Reise; Adam Savitz; Giacomo Salvadore; Qingqin Li; Robert M Bilder
Journal:  Psychiatry Res       Date:  2017-08-16       Impact factor: 3.222

3.  Alterations in facial expressivity in youth at clinical high-risk for psychosis.

Authors:  Tina Gupta; Claudia M Haase; Gregory P Strauss; Alex S Cohen; Vijay A Mittal
Journal:  J Abnorm Psychol       Date:  2019-03-14

4.  Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers.

Authors:  Brian Dean
Journal:  Schizophr Res Treatment       Date:  2011-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.